CN102143757A - 嵌合利尿钠多肽和抑制心脏重构的方法 - Google Patents

嵌合利尿钠多肽和抑制心脏重构的方法 Download PDF

Info

Publication number
CN102143757A
CN102143757A CN2009801289321A CN200980128932A CN102143757A CN 102143757 A CN102143757 A CN 102143757A CN 2009801289321 A CN2009801289321 A CN 2009801289321A CN 200980128932 A CN200980128932 A CN 200980128932A CN 102143757 A CN102143757 A CN 102143757A
Authority
CN
China
Prior art keywords
polypeptide
composition
amino acid
natriuretic
decreased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801289321A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·伯内特
陈鸿豪
O·里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Clinic in Florida filed Critical Mayo Clinic in Florida
Publication of CN102143757A publication Critical patent/CN102143757A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801289321A 2008-06-06 2009-06-03 嵌合利尿钠多肽和抑制心脏重构的方法 Pending CN102143757A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5957608P 2008-06-06 2008-06-06
US61/059,576 2008-06-06
PCT/US2009/046095 WO2009149161A2 (en) 2008-06-06 2009-06-03 Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling

Publications (1)

Publication Number Publication Date
CN102143757A true CN102143757A (zh) 2011-08-03

Family

ID=41398834

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801289321A Pending CN102143757A (zh) 2008-06-06 2009-06-03 嵌合利尿钠多肽和抑制心脏重构的方法

Country Status (8)

Country Link
US (1) US20110152194A1 (enExample)
EP (1) EP2303305A4 (enExample)
JP (1) JP2011522824A (enExample)
KR (1) KR20110020903A (enExample)
CN (1) CN102143757A (enExample)
AU (1) AU2009256222A1 (enExample)
CA (1) CA2727085A1 (enExample)
WO (1) WO2009149161A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843912A (zh) * 2016-08-18 2019-06-04 新加坡国立大学 具有血管扩张功能和/或利尿功能的肽

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
WO2012115772A2 (en) * 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US20120220528A1 (en) * 2011-02-25 2012-08-30 Medtronic, Inc. Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
EP2750697A4 (en) * 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2021183928A1 (en) * 2020-03-13 2021-09-16 Mayo Foundation For Medical Education And Research Assessing and treating acute decompensated heart failure
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AR130935A1 (es) 2022-11-02 2025-02-05 Novo Nordisk As Compuestos de cnp
WO2025054172A1 (en) 2023-09-05 2025-03-13 E-Star Biotech, LLC Formulations of manp and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044284A2 (en) * 1999-12-17 2001-06-21 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20060019890A1 (en) * 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
US20060025367A1 (en) * 1999-05-24 2006-02-02 Mayo Foundation For Medical Education And Research, A Minnesota Corporation Adenovirus vectors encoding brain natriuretic peptide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161521A (en) * 1975-08-08 1979-07-17 Merck & Co., Inc. Somatostatin analogs
US4757048A (en) * 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US20070042957A1 (en) * 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
US7803901B2 (en) * 2005-09-16 2010-09-28 Mayo Foundation For Medical Education And Research Polypeptides with natriuresis activity
TW200817431A (en) * 2006-08-08 2008-04-16 Mayo Foundation Diuretic and natriuretic polypeptides
BRPI0716228A2 (pt) * 2006-09-08 2013-10-15 Mayo Foundation Polipeptídeos aquaréticos e natriuréticos carecendo de atividade vasodilatadora
PT2765139T (pt) * 2007-07-20 2017-07-14 Mayo Foundation Polipéptidos natriuréticos
DK2307447T3 (da) * 2008-07-02 2016-06-20 Mayo Foundation Natriuretiske polypeptider med unikke farmakologiske profiler
WO2010048308A2 (en) * 2008-10-24 2010-04-29 Deborah Dickey Natriuretic polypeptides
WO2010078325A2 (en) * 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
US20120053123A1 (en) * 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
WO2011005939A2 (en) * 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025367A1 (en) * 1999-05-24 2006-02-02 Mayo Foundation For Medical Education And Research, A Minnesota Corporation Adenovirus vectors encoding brain natriuretic peptide
WO2001044284A2 (en) * 1999-12-17 2001-06-21 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20060019890A1 (en) * 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843912A (zh) * 2016-08-18 2019-06-04 新加坡国立大学 具有血管扩张功能和/或利尿功能的肽
CN109843912B (zh) * 2016-08-18 2023-04-04 新加坡国立大学 具有血管扩张功能和/或利尿功能的肽

Also Published As

Publication number Publication date
CA2727085A1 (en) 2009-12-10
WO2009149161A9 (en) 2010-04-08
JP2011522824A (ja) 2011-08-04
KR20110020903A (ko) 2011-03-03
AU2009256222A1 (en) 2009-12-10
EP2303305A2 (en) 2011-04-06
WO2009149161A2 (en) 2009-12-10
US20110152194A1 (en) 2011-06-23
EP2303305A4 (en) 2012-07-04
WO2009149161A3 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
CN102143757A (zh) 嵌合利尿钠多肽和抑制心脏重构的方法
US8455438B2 (en) Natriuretic polypeptides for reducing or preventing restenosis
US20120053123A1 (en) Natriuretic polypeptides having mutations within their disulfide rings
US10344068B2 (en) Natriuretic polypeptides
US11897931B2 (en) MANP analogues
US10336803B2 (en) Insulin secreting polypeptides
US20140274901A1 (en) Proanp compositions and methods for treating acute heart failure
US11572399B2 (en) Long-acting GIP peptide analogues
HK1160606A (en) Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
KR20250071239A (ko) Crrl 191, 심방 나트륨 이뇨 펩티드(anp) 유사체 및 구아닐릴 시클라제 수용체(gc-a)활성화제를 이용한 조성물 및 치료 방법
WO2023039453A2 (en) Dual-function polypeptides and methods for use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1160606

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110803

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1160606

Country of ref document: HK